Abstract
IntroductionUndifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established.Case presentationWe report the case of a 70‐year‐old man with undifferentiated prostate cancer and lymph node metastases. Following the patient’s progression after platinum‐based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay.ConclusionDocetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
